Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Chenodeoxycholic acid (CDCA) is a hydrophobic primary bile acid.1 It is formed from cholesterol in the liver via a multistep process catalyzed by the cytochrome P450 (CYP) isoforms CYP7A1, CYP8B1, and CYP27A1. CDCA is a farnesoid X receptor (FXR) agonist that binds to FXRs in a TR-FRET assay (EC50 = 13 µM) and induces FXR transactivation in a reporter assay.2,3 It induces transcription of the gene encoding the Nrf2 target glutamate cysteine ligase (GCL) in primary hepatocytes and HepG2 cells when used at concentrations ranging from 25 to 100 µM.4
WARNING This product is not for human or veterinary use.
1. Chenodeoxycholic acid: An update on its therapeutic applications. Bile acids and their receptors. Handbook of experimental pharmacology 256, 265-282 (2019).
2. Blimp1 is a critical determinant of the germ cell lineage in mice. Nature 436(7048), 207-213 (2005).
3. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296(5573), 1703-1706 (2002).
4. Activation of nuclear factor (erythroid-